Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

2231 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

2231 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

active not recruiting Phase II Oncology
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Trial testing niraparib combined with other drugs to treat advanced prostate cancer resistant to hormone therapy.
08 Jun 2026 NCT03431350
active not recruiting Phase III Oncology
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Trial comparing injected versus infused amivantamab with lazertinib for EGFR-mutated lung cancer, aiming to reduce treatment time.
08 Jun 2026 NCT05388669
active not recruiting Phase III Rheumatology
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
A trial testing whether JNJ-77242113 effectively treats moderate to severe plaque psoriasis in teenagers and adults.
08 Jun 2026 NCT06095115
active not recruiting Cardiology / Cardiovascular
Outcomes of Drug Coated Balloon Angioplasty, A UK Real Life Experience From 2009 to 2015
Drug-coated balloon angioplasty was safe and effective for treating coronary artery disease in this UK hospital study from 2009-2015.
08 Jun 2026 NCT03603210
● Recruiting Cardiology / Cardiovascular
Comparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication
What is being tested: Direct comparison of two transcatheter aortic valve (TAVI) systems—the self-expandable supra-annular Allegra valve versus the balloon-expandable intra-annular Edwards Sapien valve—in…
08 Jun 2026 NCT06049654
● Recruiting Phase III Oncology
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
What is being tested: A combination therapy of [225Ac]Ac-PSMA-617 (AAA817), an alpha-emitting radioligand targeting PSMA, plus an androgen receptor pathway inhibitor versus standard of…
08 Jun 2026 NCT06855277
● Recruiting Phase III Oncology
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
What is being tested: Sacituzumab tirumotecan (an antibody-drug conjugate) combined with pembrolizumab (an immune checkpoint inhibitor) as first-line maintenance therapy following chemotherapy in patients…
08 Jun 2026 NCT07216703
● Recruiting Phase III
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Nipocalimab versus placebo for preventing severe haemolytic disease in at-risk pregnancies.
05 Jun 2026 NCT05912517
active not recruiting Phase III Oncology
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Apalutamide with hormone therapy before and after prostate surgery improves cancer control in high-risk localised prostate cancer.
05 Jun 2026 NCT03767244
active not recruiting
Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms
Branched endografts (GORE EXCLUDER) successfully treat thoracoabdominal aortic aneurysms, offering minimally invasive alternative to open surgery.
05 Jun 2026 NCT03728985
active not recruiting
ATTUNE Revision System in the Revision Total Knee Arthroplasty Population
ATTUNE knee replacement prostheses showed acceptable five-year outcomes in revision surgery across two tibial design types.
05 Jun 2026 NCT03153475
active not recruiting Phase III Oncology
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Trial comparing two new bladder cancer treatments (TAR-200 with or without cetrelimab) against standard BCG therapy in untreated high-risk patients.
05 Jun 2026 NCT05714202
active not recruiting Phase III
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Remibrutinib reduces symptoms of severe hidradenitis suppurativa better than placebo, with acceptable safety in adults and teenagers.
05 Jun 2026 NCT06840392
active not recruiting Phase II Respiratory / COPD / Asthma
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Buloxibutid tested against placebo over 52 weeks in IPF patients to assess whether it slows lung function decline and is safe to use.
05 Jun 2026 NCT06588686
active not recruiting Phase II Neurology
A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer’s Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Trial testing BIIB080 injections to slow cognitive decline in people aged 50-80 with mild Alzheimer's disease or mild cognitive impairment.
05 Jun 2026 NCT05399888
● Recruiting Phase I Neurology
A Phase I Study in Healthy Volunteers and Parkinson’s Disease (PD) Patients.
What is being tested: MTX325 is being evaluated as a potential disease-modifying treatment for Parkinson's Disease, assessed initially in healthy volunteers for safety and…
05 Jun 2026 NCT07630545
● Recruiting Diabetes / Metabolic
Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease
What is being tested: The study investigates immune cell characteristics (tissue-resident and circulating), blood biomarkers, metabolic profiles, and microbiota composition (faecal and oral) to…
05 Jun 2026 NCT04141592
● Recruiting Phase III Rheumatology
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn’s Disease
What is being tested: A head-to-head comparison of two IL-23 inhibitor monoclonal antibodies—guselkumab and risankizumab—to evaluate their efficacy and safety in treating moderately to…
05 Jun 2026 NCT07499232
● Recruiting Phase IV Cardiology / Cardiovascular
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
What is being tested: The trial evaluates whether implantable/remote monitoring technology can enable early assessment of drug efficacy and guide treatment intensification decisions in…
05 Jun 2026 NCT05825417
● Recruiting Phase I Cardiology / Cardiovascular
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
What is being tested: JNJ-79635322, a novel investigational agent, is undergoing dose escalation and safety characterization in patients with relapsed or refractory multiple myeloma…
05 Jun 2026 NCT05652335
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
What is being tested: Finerenone (a non-steroidal mineralocorticoid receptor antagonist) is being evaluated for long-term safety and efficacy when combined with standard heart failure…
05 Jun 2026 NCT07192952
● Recruiting Cardiology / Cardiovascular
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
What is being tested: Real-world effectiveness, safety, and patient-reported outcomes of standard-of-care antimyeloma treatments in relapsed/refractory multiple myeloma patients over 24 months, reflecting actual…
05 Jun 2026 NCT05160584
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
What is being tested: Two bispecific antibody-based regimens (Tec-DR and Tal-DR) are being compared against standard daratumumab-lenalidomide-dexamethasone (DRd) therapy in newly diagnosed multiple myeloma…
05 Jun 2026 NCT05552222
● Recruiting Cardiology / Cardiovascular
An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias
What is being tested: Safety and performance of commercially approved Biosense Webster medical devices during routine cardiac arrhythmia mapping and ablation procedures in real-world…
05 Jun 2026 NCT04750798
● Recruiting Phase III Oncology
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
What is being tested: Amivantamab (a bispecific antibody targeting EGFR and MET) combined with pembrolizumab and carboplatin, compared to standard chemotherapy-immunotherapy combinations (pembrolizumab with…
05 Jun 2026 NCT07276399
● Recruiting Phase I Oncology
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Drug Being Tested: JNJ-88549968, a novel therapeutic agent targeting CALR-mutated myeloproliferative neoplasms (MPNs), with the study establishing safety profile, recommended phase 2 dose, and…
05 Jun 2026 NCT06150157
active not recruiting Phase III
Atrasentan in Patients With IgA Nephropathy
Atrasentan reduced kidney disease progression in IgA nephropathy patients compared to placebo.
04 Jun 2026 NCT04573478
● Recruiting
The COSP-RBD Study: Concussions and Contact Sports in RBD vs Controls
Study comparing whether people with RBD have more history of head injuries or contact sports than those without RBD.
04 Jun 2026 NCT06270290
active not recruiting Phase I / Phase II Diabetes / Metabolic
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
VX-264 trial tested a new drug's safety and effectiveness in type 1 diabetes patients.
04 Jun 2026 NCT05791201
● Recruiting Phase II
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
GTX-102 injection being tested for safety and effectiveness in treating Angelman syndrome caused by different genetic mutations.
04 Jun 2026 NCT07157254
active not recruiting Phase IV Cardiology / Cardiovascular
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
Study comparing blood thinners alone versus blood thinners with ultrasound-assisted clot-dissolving device for moderate-to-high risk blood clots in the lungs.
04 Jun 2026 NCT04790370
● Recruiting Phase III
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
Oral nizubaglustat tested against placebo for safety and effectiveness in children with rare inherited brain storage diseases.
04 Jun 2026 NCT07054515
● Recruiting Respiratory / COPD / Asthma
Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung
What is being tested: This study investigates the inflammatory and physiological profiles in healthy lungs versus diseased lungs (specifically asthma and COPD), aiming to…
04 Jun 2026 NCT06144476
● Recruiting Phase II Oncology
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
What is being tested: Inavolisib (a PI3K inhibitor) combined with enzalutamide versus standard physician-selected alternatives (other androgen receptor pathway inhibitors or docetaxel) in biomarker-selected…
04 Jun 2026 NCT07287150
● Recruiting Phase IV Oncology
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
What is being tested: Long-term safety profile of lutetium (177Lu) vipivotide tetraxetan (AAA617), a radioligand therapy targeting PSMA-positive prostate cancer, through post-marketing surveillance to…
04 Jun 2026 NCT05803941
● Recruiting Oncology
Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study
Testing focus: This study establishes PSA reference intervals (normal ranges) specifically for trans women and non-binary individuals with prostates, addressing a current evidence gap…
04 Jun 2026 NCT06987045
● Recruiting Oncology
Understanding the Feasibility of a Co-designed Pre-radiotherapy Exercise Programme – A Single-arm Study
What is being tested: A feasibility study evaluating a co-designed, pre-radiotherapy exercise programme consisting of 20-minute exercise sessions for patients with stage I-III non-small…
04 Jun 2026 NCT07554677
● Recruiting Gastroenterology
Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation
What is being tested: INTERLIVER evaluates whether microarray analysis of liver transplant biopsies can identify molecular patterns that correlate with histological findings and predict…
04 Jun 2026 NCT03193151
● Recruiting Cardiology / Cardiovascular
The “Global Paradise System” Registry
What is being tested: The GPS Registry is observing real-world outcomes in patients receiving standard clinical care, with additional collection of home blood pressure…
04 Jun 2026 NCT05027685
● Recruiting Phase II Respiratory / COPD / Asthma
Volatile Sedation for Patients With the Acute Respiratory Distress Syndrome
What is being tested: The trial compares volatile anaesthetic sedation against conventional intravenous sedation approaches in mechanically ventilated ICU patients to evaluate effects on…
04 Jun 2026 NCT06014138
● Recruiting Respiratory / COPD / Asthma
Investigating Health Related Quality of Life in Patients With Chronic Respiratory Failure
What is being tested: The study evaluates health-related quality of life (HRQoL) outcomes in patients with chronic respiratory failure and measures how clinical interventions…
04 Jun 2026 NCT04236726
● Recruiting Respiratory / COPD / Asthma
Continuation Of a Study to Investigate the Effect of Thoracocentesis on Neural Respiratory Drive in Pleural Effusion
What is being tested: The study investigates how removing fluid from around the lungs (thoracocentesis) affects neural respiratory drive—the brain's signal to breathe—in patients…
04 Jun 2026 NCT05945043
● Recruiting Cardiology / Cardiovascular
European Aortic Data Collection Project
What is being tested: Safety and real-world performance of Cook's Custom-Made Stent-graft Devices (CMD) for endovascular aortic treatment across diverse aortic pathologies through prospective…
04 Jun 2026 NCT05896397
● Recruiting Phase I Oncology
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
What is being tested: LY4584180, a novel investigational agent, is being evaluated for its safety, efficacy, pharmacokinetics, and pharmacodynamics in adults with relapsed or…
04 Jun 2026 NCT07226843
● Recruiting Phase I Oncology
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Drug Being Tested: Farletuzumab ecteribulin (MORAb-202), a folate receptor alpha (FRα)-targeting antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells expressing this receptor.…
04 Jun 2026 NCT04300556
active not recruiting Neurology
Electrical Impedance Tomography of Epilepsy
One-sentence summary: Study testing if EIT brain imaging produces accurate, reproducible results in epilepsy patients compared to MRI, CT, and EEG.
03 Jun 2026 NCT03050931
● Recruiting Phase III Neurology
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
XEN1101 added to existing treatment reduced seizures in patients with primary generalized tonic-clonic seizures compared to placebo.
03 Jun 2026 NCT05667142
active not recruiting Phase III Oncology
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Subcutaneous injection of two cancer drugs works as well as intravenous infusion for untreated advanced melanoma.
03 Jun 2026 NCT05625399
● Recruiting Phase III
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ – ColdU and SD)
Barzolvolimab reduces symptoms of cold-induced urticaria and dermographism better than placebo in patients uncontrolled on antihistamines.
03 Jun 2026 NCT07266402
active not recruiting Phase III Rheumatology
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
Monthly ianalumab injections added to standard lupus treatment reduced disease activity better than placebo.
03 Jun 2026 NCT05624749